Binnopharm Group Localised Production of an Orphan Drug

Binnopharm Group, one of Russia’s leading pharmaceutical companies, has received marketing authorisation for Eltrombopag-Alium from the Russian Ministry of Health. The drug belongs to the class of thrombopoietin receptor agonists and is intended for treatment of patients with thrombocytopenia. Manufacture of Eltrombopag-Alium will be launched at the ALIUM plant (part of the Binnopharm Group) in Obolensk, Moscow Region, in November 2025.

Localisation of production of this orphan drug (INN Eltrombopag[1]) is of strategic importance for the Russian healthcare system. Demand for this group of drug products is showing steady growth. According to DSM Group, by the end of 2024, eltrombopag entered the top five INNs in terms of import substitution volume: the share of localised drugs in monetary terms exceeded 57%. According to AlphaRM, in the first seven months of 2025, tender shipment volumes increased by 32% in physical terms compared to the same period of the previous year.

As representatives of the Binnopharm Group pointed out, «Orphan disease treatment entails significant financial costs for the budget, so import substitution of such drugs is a particularly high priority».

The ALIUM production facility was designed and built in full compliance with GMP standards, is equipped with high-tech equipment, and has a proven track record of producing a wide range of prescription and over-the-counter medications.

[1] Eltrombopag is used to treat thrombocytopenia in patients with chronic idiopathic thrombocytopenic purpura when standard therapy is ineffective, and is considered a second-line drug. The indications also extend to children over three years of age with blood diseases or severe aplastic anaemia, as well as to adult patients with chronic hepatitis C to increase the effectiveness of antiviral therapy.